Wealth Architects LLC Has $702,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wealth Architects LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,719 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Wealth Architects LLC’s holdings in Johnson & Johnson were worth $702,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Newfound Research LLC purchased a new stake in Johnson & Johnson during the third quarter valued at about $28,000. Islay Capital Management LLC bought a new position in Johnson & Johnson in the second quarter worth $42,000. FAI Wealth Management increased its holdings in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after acquiring an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC increased its holdings in Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares in the last quarter. Finally, HWG Holdings LP purchased a new position in Johnson & Johnson in the second quarter worth about $49,000. 67.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of JNJ stock opened at $146.36 on Friday. The stock has a market capitalization of $385.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The stock’s 50-day moving average price is $145.51 and its 200 day moving average price is $146.57. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.12 EPS. Analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

A number of equities analysts recently issued reports on the company. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Credit Suisse Group raised their target price on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Cantor Fitzgerald lifted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $164.93.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: What causes a yield curve to invert?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.